Skip to main content
. 2004 Jan 6;90(1):100–105. doi: 10.1038/sj.bjc.6601468

Table 2. Reasons for stopping treatment (eligible patients who started treatment).

  EMP & VBL EMP alone
n= 43 45
PSA progression 11 (25.6%) 13 (28.9%)
Death due to malignant disease 1 (2.2%)
Toxicity 13 (30.2%) 14 (31.1%)
Treatment refusal 9 (20.9%) 8 (17.8%)
Intercurrent death 1 (2.3%)
Clinical progression 9 (20.9%) 9 (20.0%)